ITI Pharma and Healthcare Fund Direct Growth
ITI Pharma and Healthcare Fund Direct Growth

ITI Pharma and Healthcare Fund Direct Growth

Compare
Equity
Direct
Sector - Healthcare

NAV: ₹ 9 as on 24-03-2023

Fund Performance
zero opening, trading, fund transfer fee
38 people have invested ₹ 37K in mutual fund in the last three months

Fund Insights

Insights icon

In the last 1 year, SBI Healthcare Opportunities Fund Direct Growth has given -2.81% return, outperforming ITI Pharma and Healthcare Fund Direct Growth by 3.08%

Insights icon

ITI Pharma and Healthcare Fund Direct Growth has one of the lowest expense ratio in the category (sector - healthcare). Its expense ratio is 0.3% which is lower than the category average expense ratio of 1.67%

ITI Pharma and Healthcare Fund Direct Growth Performance as on (24-Mar-23)

Return
1M
3M
6M
1Y
ITI Pharma and Healthcare Fund Direct Growth
-2.1%
-6.5%
-3.2%
-5.9%
Nifty 500
-1.9%
-7.4%
-3%
-2.5%
sector - healthcare
-2%
-6.9%
-4.6%
-9.8%

About the Fund

ITI Pharma and Healthcare Fund Direct Growth is an equity fund. This fund was started on  11 November, 2021. The fund is managed by Rohan Korde, Dhimant Shah, Tanay Gabhawala. The fund could potentially beat inflation in the long-run.

Key parameters

1) ITI Pharma and Healthcare Fund Direct Growth has a NAV of 9.04 as on 24-03-2023.

2) ITI Pharma and Healthcare Fund Direct Growth has 134 Cr worth of assets under management (AUM) as on 31-01-2023 and is less than category average.

3) The fund has an expense ratio 0.3 %.

ITI Pharma and Healthcare Fund Direct Growth Overview

Expense ratio
Expense ratio
0.3%
Benchmark
Benchmark
S&P BSE Healthcare PR
AUM
AUM
₹134 Cr
Inception Date
Inception Date
11 November, 2021
Min Lumpsum/SIP
Min Lumpsum/SIP
₹5000/₹500
Exit Load
Exit Load
1%
Lock In
Lock In
No Lock-in
TurnOver
TurnOver
0%

Fund Distribution as on (28-Feb-23)

  • Equity 97.3%

  • Debt & Cash 2.7%

Size breakup

Large cap
57.7%
Mid cap
19.3%
Small cap
17.8%

Sector Allocation

Feb'23

Jan'23

Dec'22

Health

95.9%

Basic Materials

4.1%

Top Holdings of ITI Pharma and Healthcare Fund Direct Growth as on (28-Feb-23)

  • Equity

Equity Holdings28

ITI Pharma and Healthcare Fund Direct Growth: Monthly Changes Updates

All changes are between Dec'22 and Feb'23

Fund Performance

Feb'23
Jan'23
Dec'22
Fund Returns
-4.39%
-1.42%
-3.58%
Nifty 500
-2.22%
-3.79%
-3.47%
  • This fund’s returns stands at -4.39% whereas the fund’s underlying benchmark Nifty 500 returns stands at -2.22% as on Feb'23
  • This fund underperformed Nifty 500 by 2.17% in Feb'23

AUM Change

Parameters
Feb'23
Jan'23
Dec'22
AUM
₹ 147.1 Cr
₹ 147.1 Cr
₹ 164.6 Cr
  • AUM of the fund stands at 147.1 Cr as of Feb'23
  • AUM has remained same between Feb'23 and Jan'23

Fund Portfolio Changes

Top Stocks bought last month
Apollo Hospitals Enterprise Ltd's allocation increased from 2.4% to 4.26%
Apollo Hospitals Enterprise Ltd's allocation increased from 2.4% to 4.26%
Sun Pharmaceuticals Industries Ltd's allocation increased from 22.73% to 24.1%
Sun Pharmaceuticals Industries Ltd's allocation increased from 22.73% to 24.1%
Dr Reddy's Laboratories Ltd's allocation increased from 6.67% to 7.05%
Dr Reddy's Laboratories Ltd's allocation increased from 6.67% to 7.05%
Top Stocks sold last month
Cipla Ltd's allocation decreased from 8.98 % to 8.39 %
Cipla Ltd's allocation decreased from 8.98 % to 8.39 %
Divi's Laboratories Ltd's allocation decreased from 6.74 % to 6.29 %
Divi's Laboratories Ltd's allocation decreased from 6.74 % to 6.29 %
Alkem Laboratories Ltd's allocation decreased from 2.75 % to 2.54 %
Alkem Laboratories Ltd's allocation decreased from 2.75 % to 2.54 %
Small Cap allocation has gone down from 18% to 17.8%
Small Cap allocation has gone down from 18% to 17.8%
Mid Cap allocation has gone down from 22.1% to 19.3%
Mid Cap allocation has gone down from 22.1% to 19.3%
Large Cap allocation has gone up from 56.8% to 57.7%
Large Cap allocation has gone up from 56.8% to 57.7%
Cash allocation has gone up from 0.7% to 2.7%
Cash allocation has gone up from 0.7% to 2.7%

Top 2 Sectors in February were Health, Basic Materials

Feb'23
Health
96%
Basic Materials
4%
Jan'23
Health
97%
Basic Materials
3%

Gainers & Losers in ITI Pharma and Healthcare Fund Direct Growth portfolio as on (28-Feb-23)

ITI Pharma and Healthcare Fund Direct Growth Fund Manager

Rohan Korde

Rohan Korde

Fund Manager of ITI Pharma and Healthcare Fund Direct Growth, since 11 November 2021
Dhimant Shah

Dhimant Shah

Fund Manager of ITI Pharma and Healthcare Fund Direct Growth, since 1 December 2022
Tanay Gabhawala

Tanay Gabhawala

Fund Manager of ITI Pharma and Healthcare Fund Direct Growth, since 21 October 2022

Fund Highlights

Risk meter
pointer

Very High Risk

Investors understand that their principal will be at Very High Risk
Fund Allocations

Fund Allocations

This fund has an allocation of 97.28% in Equity, 0% in Debt and 2.72% in Cash related instruments
AUM size ₹134 Cr

AUM size ₹134 Cr

This fund has AUM of ₹134 Cr which is less than its category average of ₹ 1251 Cr
Expense Ratio 0.3%

Expense Ratio 0.3%

This fund has an expense ratio of 0.3% which is less than its category average expense ratio of 1.56%

Frequently Asked Questions

The current NAV of ITI Pharma and Healthcare Fund Direct Growth is 9.06 as on 22-Mar-2023.
Existing (Absolute + CAGR)
ITI Pharma and Healthcare Fund Direct Growth
Absolute Returns
CAGR Returns
1 Month Returns
-1.79%
-1.79%
6 Month Returns
-3.35%
-3.35%
1 Year Returns
-4.31%
-4.31%
3 Years Returns
0%
0%
5 Years Returns
0%
0%
With INDmoney, the process of investing is very simple and involves zero commission.
  • Click Buy on the fund name.
  • Input the amount you are looking to invest.
  • Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
  • Select your bank account and proceed with Payment.
0.3 as on February 2023
134 Cr as on February 2023
Sun Pharmaceuticals Industries Ltd(23.41%),Cipla Ltd(9.12%),Dr Reddy's Laboratories Ltd(7.38%),Torrent Pharmaceuticals Ltd(7.07%),Divi's Laboratories Ltd(5.87%) as on February 2023
Health(93.34%),Basic Materials(3.95%),Cash Equivalent(2.72%) as on February 2023
The alpha ratio for the ITI Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Alpha 1 Year
Alpha 3 Years
Alpha 5 Years
ITI Pharma and Healthcare Fund Direct Growth
4.58
-
-
As on February 2023
The alpha for ITI Pharma and Healthcare Fund Direct Growth is calculated against S&P BSE Healthcare PR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the ITI Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Beta 1 Year
Beta 3 Years
Beta 5 Years
ITI Pharma and Healthcare Fund Direct Growth
0.94
-
-
As on February 2023
The Beta for ITI Pharma and Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the ITI Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Sharpe Ratio 1 Year
Sharpe Ratio 3 Years
Sharpe Ratio 5 Years
ITI Pharma and Healthcare Fund Direct Growth
-0.45
-
-
As on February 2023
The sharpe ratio for ITI Pharma and Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the ITI Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Standard Deviation 1 Year
Standard Deviation 3 Years
Standard Deviation 5 Years
ITI Pharma and Healthcare Fund Direct Growth
13.52
-
-
As on February 2023
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
Rohan Korde,Tanay Gabhawala,Dhimant Shah are the fund managers of ITI Pharma and Healthcare Fund Direct Growth
The Exit load of ITI Pharma and Healthcare Fund Direct Growth is 1%